<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893669</url>
  </required_header>
  <id_info>
    <org_study_id>NBP607_Flu_I_2012</org_study_id>
    <nct_id>NCT03893669</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults</brief_title>
  <official_title>Randomized, Double-blinded, Controlled, Phase I Trial to Assess Safety, Tolerability and Immunogenicity of 'NBP607(Trivalent Inactivated Cell-Culture Influenza Vaccine)' Compared to Egg-based Influenza Vaccine in Healthy Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blinded, controlled, Phase I clinical trial to assess the safety,
      tolerability and immunogenicity of 'NBP607(trivalent inactivated cell-culture influenza
      vaccine)' compared to egg-based influenza vaccine in healthy adult volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Assessment of Safety

        2. Assessment of Immunogenicity

        3. Estimated Enrollment: 100
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of solicited local adverse events (AEs)</measure>
    <time_frame>Within 21 days after vaccination</time_frame>
    <description>All AEs were classified and analyzed according to its severity and causality. The number and percentage of subjects with AEs were analyzed. Incidence rate, 95% confidence interval as well as number of occurrences were calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of solicited systemic AEs</measure>
    <time_frame>Within 21 days after vaccination</time_frame>
    <description>All AEs were classified and analyzed according to its severity and causality. The number and percentage of subjects with AEs were analyzed. Incidence rate, 95% confidence interval as well as number of occurrences were calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of unsolicited AEs</measure>
    <time_frame>Within 21 days after vaccination</time_frame>
    <description>All AEs were classified and analyzed according to its severity and causality. The number and percentage of subjects with AEs were analyzed. Incidence rate, 95% confidence interval as well as number of occurrences were calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse rate at each visit</measure>
    <time_frame>0-14 days prior to vaccination/day of vaccination/3-7 days after vaccination/21-28 days after vaccination</time_frame>
    <description>Comparisons within each group between pre-/post- vaccination were summarized and presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure(systolic/diastolic) at each visit</measure>
    <time_frame>0-14 days prior to vaccination/day of vaccination/3-7 days after vaccination/21-28 days after vaccination</time_frame>
    <description>Comparisons within each group between pre-/post- vaccination were summarized and presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body temperature at each visit</measure>
    <time_frame>0-14 days prior to vaccination/day of vaccination/3-7 days after vaccination/21-28 days after vaccination</time_frame>
    <description>Comparisons within each group between pre-/post- vaccination were summarized and presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of normal/abnormal results in Electrocardiogram (ECG) (ventricular rate, PR interval, QRS, QT, and QTc) collected during screening visit and close-out visit</measure>
    <time_frame>Screening visit(0-14 days prior to vaccination)/close-out visit(21-28 days after vaccination)</time_frame>
    <description>Comparisons within each group between pre-/post- vaccination were summarized and presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of normal/abnormal results in physical examination at each visit</measure>
    <time_frame>0-14 days prior to vaccination/day of vaccination/3-7 days after vaccination/21-28 days after vaccination</time_frame>
    <description>Comparisons within each group between pre-/post- vaccination were summarized and presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of normal/abnormal results in clinical laboratory tests(Platelet, Cl, etc.) during screening visit and close-out visit</measure>
    <time_frame>Screening visit(0-14 days prior to vaccination)/close-out visit(21-28 days after vaccination)</time_frame>
    <description>Comparisons within each group between pre-/post- vaccination were summarized and presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate measured by pre-/post-vaccination Haemagglutination Inhibition (HI) titer[Immunogenicity]</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>The proportion of subjects achieving one of the following conditions; i)If the pre-vaccination HI titer were &lt;1:10, subjects achieving an HI titer ≥1:40 after vaccination ii)If the pre-vaccination HI titers were ≥1:10, subjects with a minimum 4-fold rise in HI titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMR) measured by pre-/post-vaccination HI titer[Immunogenicity]</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>The mean increase in geometric mean HI titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate measured by post-vaccination HI titer[Immunogenicity]</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>The proportion of subjects with post-vaccination HI titers of ≥1:40</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Prevention of Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NBP607 0.5ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Agrippal 0.5ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NBP607</intervention_name>
    <description>1 dose, 0.5ml, Intramuscular (IM) injection</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Agrippal</intervention_name>
    <description>1 dose, 0.5ml, Intramuscular (IM) injection</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20 to &lt;60 years of age

          2. able and willing to give written informed consent prior to study entry

          3. if female, at least 2 years after post- menopausal and negative result of urine-human
             chorionic gonadotropin (HCG) test at screening

        Exclusion Criteria:

          1. hypersensitivity to any component of the study medication or chemically related
             substances, such as allergy to eggs or egg products

          2. Immunodeficiency disease

          3. history of hypersensitivity when vaccination, such as Guillain-Barre syndrome

          4. thrombocytopenia or Coagulation disorders

          5. experienced fever (&gt;37.5°C) within the past 24 hours or any acute respiratory
             infection

          6. receipt of Immunosuppressants or Immunomodulators within the past 3 months

          7. receipt of blood products or immunoglobulin within the past 3 months

          8. received influenza vaccine within the past 6 months

          9. received another vaccine within the past 1 month or plans vaccination within 1 months
             following the study vaccination

         10. participation on another clinical trial within 1 month prior to the study vaccination

         11. history of blood donation within 1 week prior to the study vaccination for plan of
             blood donation within 7 days following the study vaccination

         12. any chronic diseases that interfere with the clinical trial or Malignant tumors

         13. pregnant or breastfeeding

         14. any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives or might interfere with the safety of the study
             subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo Joo Kim, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro-gu</state>
        <zip>153-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

